Healthy Skepticism
Join us to help reduce harm from misleading health information.
Increase font size   Decrease font size   Print-friendly view   Print
Register Log in

Healthy Skepticism Library

Items published during the years 1990 to 1999

There are 2362 items in the Healthy Skepticism Library that were published during the years 1990 to 1999.

Page 2 of 24 pages  < 1 2 3 4 >  Last ›

Hansen K
S4 advertising in mainstream press
Australian Medicine 1999 July 53

Bates DW, Teich JM, Lee J, Seger D, Kuperman GJ, Ma'Luf N, Boyle D, Leape L.
The impact of computerized physician order entry on medication error prevention.
J Am Med Inform Assoc 1999 Jul-Aug 01; 6:(4):313-21

Eckardt VF.
[Promoting research and graduate education by the pharmaceutical industry--scientific progress or marketing strategy?]
Z Gastroenterol. 1999 Jul; Suppl 2:19-27

Elstein AS.
Heuristics and biases: selected errors in clinical reasoning.
Acad Med 1999 Jul; 74:(7):791-4

Chepesiuk R.
Keeping pharmaceutical advertising on track.
Can Fam Physician 1999 Jul; 45:1652-3:

Neuman SL.
Year 2000 in pharmacy: business as usual or disaster in progress?
Journal of Managed Care Pharmacy 1999 Jul-Aug; 5:305, 308-310

Wang JC.
Beyond DTC: what to do if FDA scales back DTC advertising
Pharmaceutical Executive 1999 Jul; 19:58-60

Sesti LM.
Principles of pharmacy . . . ethics & practice. Part 2
Michigan Pharmacist 1999 Jul-Aug; 37:44-45

Smith D.
Risk management: consumer holds the trump card
Pharmaceutical Executive 1999 Jul; 19:2

Morris L.
Reminder and help-seeking ads: alive and well
Pharmaceutical Executive 1999 Jul; 19:14

West D.
DTC decisions: from revolution to evolution
Pharmaceutical Executive 1999 Jul; 19:4-6, 8

Breu J.
Will patent-holder's tactics forestall generic competition?
Drug Topics 1999 Jul; 143:

Lurie P, Wolfe SM
Proposed revisions to the Declaration of Helsinki. Paving the way for globalization in research.
Western Journal of Medicine 1999 Jul; 171:(1):6

Warlow C, Sandercock P, Dennis M, Wardlaw J.
Research funding.
Lancet 1999 Jun 26; 353:(9171):2250

Matthews JNS
Sponsored trials do not necessarily give more-favourable results
BMJ 1999 Jun 26; 318:1762

Koepp R, Miles SH.
Meta-analysis of tacrine for Alzheimer disease: the influence of industry sponsors.
JAMA 1999 Jun 23-30; 281:(24):2287-8

Galewitz P.
Study: Drugmaker Ads Can Backfire
AP Business Writer 1999 Jun 17

Lexchin J.
PMAC code of marketing practices.
CMAJ 1999 Jun 1; 160:(11):1556

Wolfe S, Sasich L
The Wild, Wild Web
The Washington Post 1999 Jun 1

Williams AH, Rowell M.
Private enterprise and public good: ethical issues in the funding of clinical research.
Ann R Coll Physicians Surg Can 1999 Jun; 32:(4):227-31

Bell RA, Wilkes MS, Kravitz RL.
Advertisement-induced prescription drug requests: patients' anticipated reactions to a physician who refuses.
J Fam Pract 1999 Jun; 48:(6):446-52

Lexchin J.
Re: the promotion of Atrovent (ipratropium bromide)
1999 Jun;

Smith D.
Who says consumers can't make decisions?
Pharmaceutical Executive 1999 Jun; 19:19

Prince R.
Generic firms seek government help to fight manufacturers for drug marketing rights
Pharmacy Practice News 1999 Jun; 26:1, 16

West D.
Crop at the top: popular ad shops of the DTC world
Pharmaceutical Executive 1999 Jun; 19:6-8, 10, 12, 14

Wechsler J.
Risky business
Pharmaceutical Executive 1999 Jun; 19:3

Rolland PD, Kablinger AS.
Recruitment for clinical trials: psychopharmacology research clinic's experience in recruiting for depression studies
ASHP Annual Meeting 1999 Jun; 56:

Hatwig CA, Ritz P, Nunan R, Ferer M, Dunwoody C.
Designing and implementing a public relations campaign for pharmacists
ASHP Annual Meeting 1999 Jun; 56:

Mansour P.
More lessons from unfortunate events in Toronto.
Lancet 1999 May 29; 353:(9167):1888

Bremer S.
Let the good times roll
Chemist and Druggist 1999 May 29; 251:16, 18, 20

Wolfe S, Lurie P
Comments in correspondence section in response to article entitled 'Science, ethics, and future of research into maternal-infant transmission of HIV-1'
The Lancet 1999 May 29; 353:9167

Donohoe MT, Matthews H.
Wasted paper in pharmaceutical samples.
N Engl J Med 1999 May 20; 340:(20):1600

Lexchin J
Rethinking the numbers on adverse drug reactions
JAMC 1999 May 18; 160:(10):1432

Dieppe P, Chard J, Tallon D, Egger M.
Funding clinical research.
Lancet 1999 May 8; 353:(9164):1626

Does continuing medical education in general practice make a difference?
Cantillon P, Jones R
BMJ 1999 May 8; 318:(7193):1276-9

Chan DH, Leclair K, Kaczorowski J.
Problem-based small-group learning via the Internet among community family physicians: a randomized controlled trial.
MD Comput 1999 May-Jun 01; 16:(3):54-8

Lexchin J.
How patient outcomes are reported in drug advertisements.
Can Fam Physician 1999 May; 45:1213-6:

Dr. Celebrity
Consumer Reports 1999 May8-9

Molloy DW, Smith SD, Jubelis RM.
The Ideal Detail Program - comprehensive, up-to-date drug detailing
Health Law in Canada 1999 May; 19:(4):89-95

Paytash CA.
The learned intermediary doctrine and patient package inserts: a balanced approach to preventing drug-related injury.
Stanford Law Rev 1999 May; 51:(5):1343-71

West D.
Sensitivity training
Pharmaceutical Executive 1999 May; 19:

Smith DL.
Your patient package insert: does it help or hinder?
Pharmaceutical Executive 1999 May; 19:

West D.
Remote control? DTC ponders the twilight zone of TV advertising
Pharmaceutical Executive 1999 May; 19:

Wechsler J.
Regulating the Internet
Pharmaceutical Executive 1999 May; 19:

Lee TH.
Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
Am Heart J. 1999 May; 137:(5):S67-70

Hanson JD, Kysar DA.
Taking behavioralism seriously: some evidence of market manipulation
Harv Law Rev. 1999 May; 112:(7):1420-572.

Guidelines for evaluating papers on educational interventions
BMJ 1999 May; 318:1265-1267

Wang TJ, Ausiello JC, Stafford RS.
Trends in antihypertensive drug advertising, 1985-1996.
Circulation 1999 Apr 20; 99:(15):2055-7

Conlan MF.
Hot issues
Drug Topics 1999 Apr 19; 143:80-82, 84, 87, 89

APhA sets policy on telepharmacy, DTC ads, unions
American Journal of Health System Pharmacy 1999 Apr 15; 56:706-707

Working Group on Women and Health Protection
To do no harm: DTC advertising of prescription drugs
1999 Apr 12

Schonhofer PS
Dipyrone (Metamizol): Restored to good repute?
Internistische Praxis 1999 Apr 0939:184-185

Health Products and Food Branch, Health Canada.
Direct-to-consumer advertising of prescription drugs. [discussion document].
: Health Products and Food Branch, Health Canada. 1999 Apr 6

Therapeutic Products Programme
Discussion document: direct-to-consumer advertising of prescription drugs
1999 Apr 6

Hutchinson JM, Foley RN
Method of physician remuneration and rates of antibiotic prescription
CMAJ 1999 Apr 6; 160:(7):1013–1017

Leach B.
Marketing forces
The Health Exchange 1999 Apr8-9

Pharmaceutical Manufacturers Association of Canada
Advertising of prescription medicines to Canadian consumers: PMAC’s position
Ottawa: Pharmaceutical Manufacturers Association of Canada 1999 Apr

Hayes L, Smith D.
Drug industry sponsorship: at what price?
HAI News 1999 Apr; (106):1-2, 15-16

Nolan A.
Issues & priorities for the pharmaceutical industry in Ireland
Irish Pharmacy Journal 1999 Apr; 77:112-114

Buckley B.
Prescriptions grow 7% to 2.4 billion; sales increase 16% to $94 billion
Pharmacy Times 1999 Apr; 65:16-18, 21-22

Mangione-Smith R, McGlynn EA, Elliott MN, Krogstad P, Brook RH.
The relationship between perceived parental expectations and pediatrician antimicrobial prescribing behavior.
Pediatrics 1999 Apr; 103:(4):

Rizzo JA
Advertising and competition in the ethical pharmaceutical industry: the case of antihypertensive drugs
J Law Econ 1999 Apr; 42:(1):89–116

Ragg M.
Capsule or pill, don't swallow it whole
Weekend Australian 1999 Mar 27

Rankin P
Offensive to GPs
Australian Doctor 1999 Mar 1926

Murphy JE.
Generic substitution and optimal patient care.
Arch Intern Med 1999 Mar 8; 159:(5):429-33

Nathan DG, Weatherall DJ.
Academia and industry: lessons from the unfortunate events in Toronto.
Lancet 1999 Mar 6; 353:(9155):771-2

Sweet M
Getting to the consumer direct
Australian Doctor 1999 Mar 529

Razack S, Arbour L, Hutcheon R.
Proposed model for interaction between residents and residency training programs, and pharmaceutical industry.
Ann R Coll Physicians Surg Can 1999 Mar; 32:(2):93-6

Law J.
Who will be the new voice of patients?
Scrip Magazine 1999 Mar30-33

Memoirs of methods used to sell drugs
MaLAM International News 1999 Mar-Apr; 17:(3-4):1-6

Kravetz S.
Pharmacy profession unites to endorse collaborative drug therapy management
Pharmacy Practice News 1999 Mar; 26:10, 18

Wilcock M.
Take the heat out of prescribing
Pharmacy in Practice 1999 Mar; 9:86-87

Bloom MZ.
Direct-to-consumer advertising provides challenge to managed care
Journal-of-Managed-Care-Pharmacy 1999 Mar-Apr; 5:101-103, 106

Wechsler J.
Taking steps toward harmonization with Europe and Japan
Pharmaceutical Technology 1999 Mar; 23:16, 18, 20-22, 24, 26, 28, 30

Consumers want details about prescription drugs; many use alternative medicines
American Journal of Health System Pharmacy 1999 Feb 15; 56:307

Wahlbeck K, Adams C.
Beyond conflict of interest: Sponsored drug trials show more-favourable outcomes.
BMJ 1999 Feb 13; 318:(7181):465

Cresswell A
Plan for GPs to share prescription savings
Australian Doctor 1999 Feb 122

Shuchman M.
Independent review adds to controversy at Sick Kids.
CMAJ 1999 Feb 9; 160:(3):386-8

Mandelkern M.
Manufacturer support and outcome.
J Clin Psychiatry 1999 Feb; 60:(2):122-3

Advertising of antibacterials
Health Skepticism 1999 Feb; 2:(2):1-5

Troy T.
Clinical independence meets demands of government, health care users
Managed Healthcare 1999 Feb; 9:30

Zoeller J.
Top 200 drugs: aggressive detailing and direct-to-consumer advertising are landing new products in the top 200 rankings much sooner
American Druggist 1999 Feb; 216:41-44, 46, 48

West D.
United they stand: patient care providers and DTC campaigns shake on it
Pharmaceutical Executive 1999 Feb; 2:6-8

Greenhalgh T.
Narrative based medicine: narrative based medicine in an evidence based world.
BMJ 1999 Jan 30; 318:(7179):323-5

Hollon MF.
Direct-to-consumer marketing of prescription drugs: creating consumer demand.
JAMA 1999 Jan 27; 281:(4):382-4

Holmer AF.
Direct-to-consumer prescription drug advertising builds bridges between patients and physicians.
JAMA 1999 Jan 27; 281:(4):380-2

Landis NT.
Requirements for FDA-approved patient information spelled out in final rule
American Journal of Health System Pharmacy 1999 Jan 15; 56:107-108

Landis NT.
Community pharmacy pricing suit dismissed
American Journal of Health System Pharmacy 1999 Jan 15; 56:113

Zuger A.
Fever Pitch: Getting Doctors To Prescribe Is Big Business
New York Times 1999 Jan 11

Ravindran GD.
The physician and the pharmaceutical industry: both must keep the patient's interests at heart.
Issues Med Ethics 1999 Jan-Mar; 7:(1):21-2

Advertising of CCBs for hypertension
Health Skepticism 1999 Jan; 2:(1):3-4

Lexchin J.
Re: the promotion of Zaditen (ketotifen)
1999 Jan;

Gilderman A, Salas JC, Khoury-Chamoun L.
The effectiveness of an antibiotic use program.
Manag Care Interface 1999 Jan; 12:(1):73-6

Wechsler J.
Policy issues for 1999
Pharmaceutical Executive 1999 Jan; 19:20, 22, 26

Wechsler J.
Prices, patients, privacy top 1999 agenda
Pharmaceutical Technology 1999 Jan; 23:14, 16-18, 20, 22, 24, 27

Gaedeke RM, Tootelian DH, Sanders EE.
Value of services provided by pharmaceutical companies: perceptions of physicians and pharmaceutical sales representatives.
Health Mark Q 1999; 17:(1):23-31

Heuer RJ.
. Psychology of Intelligence Analysis : Center for the Study of Intelligence, US Central Intelligence Agency 1999

Dolovich L, Levine M, Tarajos R, Duku E.
Promoting optimal antibiotic therapy for otitis media using commercially sponsored evidence-based detailing: A prospective controlled trial.
Drug Information Journal 1999; 33:(4):1067-1077

Jones M, Greenfield S, Bradley C
A survey of the advertising of nine new drugs in the general practice literature.
Journal of Clinical Pharmacy and Therapeutics 1999; 24:451-460

A farewell to sales reps
Prescrire International 1999; 8:(41):66

Page 2 of 24 pages  < 1 2 3 4 >  Last ›


  Healthy Skepticism on RSS   Healthy Skepticism on Facebook   Healthy Skepticism on Twitter

Click to Register

(read more)

Click to Log in
for free access to more features of this website.

Forgot your username or password?

You are invited to
apply for membership
of Healthy Skepticism,
if you support our aims.

Pay a subscription

Support our work with a donation

Buy Healthy Skepticism T Shirts

If there is something you don't like, please tell us. If you like our work, please tell others.

Far too large a section of the treatment of disease is to-day controlled by the big manufacturing pharmacists, who have enslaved us in a plausible pseudo-science...
The blind faith which some men have in medicines illustrates too often the greatest of all human capacities - the capacity for self deception...
Some one will say, Is this all your science has to tell us? Is this the outcome of decades of good clinical work, of patient study of the disease, of anxious trial in such good faith of so many drugs? Give us back the childlike trust of the fathers in antimony and in the lancet rather than this cold nihilism. Not at all! Let us accept the truth, however unpleasant it may be, and with the death rate staring us in the face, let us not be deceived with vain fancies...
we need a stern, iconoclastic spirit which leads, not to nihilism, but to an active skepticism - not the passive skepticism, born of despair, but the active skepticism born of a knowledge that recognizes its limitations and knows full well that only in this attitude of mind can true progress be made.
- William Osler 1909